Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Growth Rate of the Adult Malignant Glioma Therapeutics Market?
The market size of therapeutics for adult malignant glioma has seen a swift expansion in the last few years. Predictions indicate it will escalate from a worth of $2.25 billion in 2024 to reach a value of $2.48 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 10.4%. Factors such as rising occurrence rates, patient advocacy initiatives, and personalized medicine strategies account for this significant growth during the historical period.
What Growth Rate Is Forecasted for the Adult Malignant Glioma Therapeutics Market by 2029?
The market for adult malignant glioma therapeutics is expected to experience substantial growth in the upcoming years, reaching a value of $3.55 billion by 2029, with a compound annual growth rate (CAGR) of 9.4%. This anticipated growth during the forecast period is owing to advancements in immunotherapy, targeted therapies, the discovery of biomarkers, applications of liquid biopsy, and broadened access programs. The main trends expected in the forecast period encompass patient-focused drug development, fast-track and breakthrough designation, progress in drug delivery systems, collaborative research initiative, and the integration of artificial intelligence.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13178&type=smp
Which Key Companies Are Shaping the Future of the Adult Malignant Glioma Therapeutics Market?
Major companies operating in the adult malignant glioma therapeutics market report are Johnson & Johnson Private Limited, Pfizer Inc., Bio-Rad Laboratories Inc., F. Hoffmann-La Roche Ltd., Allergan PLC, AbbVie Inc., Novartis AG, Bayer AG, Merck & Co Inc., GlaxoSmithKline PLC, Bristol-Myers Squibb Company, Abbott Laboratories, AstraZeneca PLC, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., GT Medical Technologies Inc., Lupin Limited, Mylan NV, Sanofi SA, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Genetech Inc., Amneal Pharmaceuticals LLC, Emcure Pharmaceuticals Limited, Novocure Ltd., Arbour Pharmaceuticals LLC, Basilea Pharmaceuticals Ltd.
Which Factors Are Driving Demand in the Adult Malignant Glioma Therapeutics Industry?
The increase in brain tumor cases is anticipated to fuel the growth of the adult malignant glioma therapeutics market. Brain tumors represent an abnormal accumulation of tissue, in which typical cell-regulating mechanisms fail to control rampant cell growth and multiplication. Adult malignant glioma is a specific type of brain tumor comprising cells that exhibit abnormal and uncontrollable growth. The treatment of adult malignant glioma involves a combination of surgery, radiation therapy, and chemotherapy. For instance, the American Cancer Society, a US-based nonprofit cancer advocacy organization, reported a rise in cases of brain and nervous system cancer to 24,810 in January 2023, showing a 3.85% growth from 23,890 cases in 2020. Consequently, the rising incidence of brain tumors is boosting the adult malignant glioma therapeutics market.
Adult Malignant Glioma Therapeutics Market Driver: Government Funding Stimulating Improvements In Adult Malignant Glioma Therapeutics
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=13178&type=smp
How Is the Adult Malignant Glioma Therapeutics Market Segmented by Several Divisions?
The adult malignant glioma therapeutics market covered in this report is segmented –
1) By Type Of Disease: Glioblastoma Multiforme, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Anaplastic Oligoastrocytoma, Other Types
2) By Therapy: Chemotherapy, Targeted Therapy, Radiotherapy, Other Therapies
3) By End-User: Hospitals, Specialty Clinics, Cancer And Radiation Therapy Centers, Other End Users
Subsegments:
1) By Glioblastoma Multiforme: Standard Treatments, Experimental Therapies
2) By Anaplastic Astrocytoma: Chemotherapy Options, Targeted Therapies
3) By Anaplastic Oligodendroglioma: Radiation Therapy, Combination Therapies
4) By Anaplastic Oligoastrocytoma: Surgical Interventions, Adjuvant Therapies
5) By Other Types: Rare Gliomas, Emerging Therapies
What are the Emerging Market Trends Driving the Growth of the Adult Malignant Glioma Therapeutics Industry?
Leading firms in the adult malignant glioma therapeutics market are spearheading the development of cutting-edge products like small molecule targeted degraders to ensure top-notch customer care. These degraders are drugs that use small molecules to prompt the degradation of certain proteins by specifically targeting the protein of interest (POI) and an E3 ubiquitin ligase. Take Beactica Therapeutics AB, a Swedish precision oncology company, for example. In February 2023, they were granted orphan drug designation approval by the U.S. Food and Drug Administration (FDA) for their drug, BEA-17, as a treatment for glioblastoma (GBM). This drug, a small-molecule targeted degrader, is designed to degrade the epigenetic enzyme LSD1 and its co-factor CoREST, both of which have been associated with the development of various types of cancer, including GBM. By degrading LSD1 and CoREST, BEA-17 reactivates tumor suppressor genes and inhibits the growth of cancer cells.
Access The Full Report Here:
Which Regions Are Driving Growth in the Adult Malignant Glioma Therapeutics Market?
North America was the largest region in the adult malignant glioma therapeutics market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the adult malignant glioma therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13178
This Report Delivers Insight On:
1. How big is the adult malignant glioma therapeutics market, and how is it changing globally?
2. Who are the major companies in the adult malignant glioma therapeutics market, and how are they performing?
3. What are the key opportunities and risks in the adult malignant glioma therapeutics market right now?
4. Which products or customer segments are growing the most in the adult malignant glioma therapeutics market?
5. What factors are helping or slowing down the growth of the adult malignant glioma therapeutics market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
